Ketorolac during the induction phase of cyclosporin-A therapy

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 2, 2006, Pages 150-154

  Schechter, Barry A ^a  

^a Florida Eye Microsurgical Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACULAR LS; CYCLOSPORIN A; KETOROLAC;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL TRIAL; COMFORT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA STAINING; DIAGNOSTIC TEST; DRUG EFFICACY; DRY EYE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SCORING SYSTEM; STAINING; TEAR BREAK UP TIME TEST;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; DRY EYE SYNDROMES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KETOROLAC; MALE; TREATMENT OUTCOME;

EID: 33646711858     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.150     Document Type: Article

References (17)

1. Brewitt, H., and Sistani, F. Dry eye disease: The scale of the problem. Surv. Ophthalmol. 45(Suppl):199-202, 2001.
2. Schaumberg, D.A., Sullivan, D.A., Buring, J.E., et al. Prevalence of dry eye syndrome among U.S. women. Am. J. Ophthalmol. 136:318-326, 2003.
3. Perry, H.D., and Donnenfeld, E.D. Topical 0.05% cyclosporine in the treatment of dry eye. Exp. Opin. Pharmacother. 5:2099-2107, 2004.
4. Pflugfelder, S.C. Antiinflammatory therapy for dry eye. Am. J. Ophthalmol. 137:337-342, 2004.
5. Guerrissi, J.O., and Belmonte, J. Surgical treatment of dry eye syndrome: Conjunctival graft of the minor salivary gland. J. Craniofac. Surg. 15:6-10, 2004.
6. Kunert, K.S., Tisdale, A.S., Stern, M.E., et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch. Ophthalmol. 118:1489-1496, 2000.
7. Sail, K., Stevenson, O.D., Mundorf, T.K., et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology 107:631-636, 2000.
8. Cross, W.D., Lay, L.F., Jr., Walt, J.G., et al. Clinical and economic implications of topical cyclosporine-A for the treatment of dry eye. Manag. Care Interface 15:44-19, 2002.
9. Small, D.S., Acheampong, A., Reis, B., et al. Blood concentrations of cyclosporine-A during long-term treatment with cyclosporine-A ophthalmic emulsions in patients with moderate to severe dry eye disease. J. Ocul. Pharmacol. Ther. 18:411-418, 2002.
10. Bertelmann, E., and Pleyer, U. Immunomodulatory therapy in ophthalmology-is there a place for topical application? Ophthalmologica 218:359-367, 2004.
11. Ishida, Y., Kato, T., Minamoto, A., et al. Retinal pigment epithelial tear in a patient with central serous chorioretinopathy treated with corticosteroids. Retina 24:633-636, 2004.
12. Yeung, C.K., Chan, K.P., Chan, C.K., et al. Cytotoxicity of triamcinolone on cultured human retinal pigment epithelial cells: Comparison with dexamethasone and hydrocortisone. Jpn. J. Ophthalmol. 48:236-242, 2004.
13. Garrott, H.M., and Walland, M.J. Glaucoma from topical corticosteroids to the eyelids. Clin. Exp. Ophthalmol. 32:224-226, 2004.
14. Price, M.O., and Price, F.W. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr. Med. Res. Opin. 20:2015-2019, 2004.
15. Solomon, K.D., Donnenfeld, E.D., Raizman, M., et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in postphotorefractive keratectomy patients. J. Cataract Refract. Surg. 30:1653-1660, 2004.
16. Flach, A.J. Corneal melts associated with topically applied nonsteroidal anti-inflammatory drugs. Trans. Am. Ophthalmol. Soc. 2001. 99:205-210, discussion 210-212.
17. Gaynes, B.I., and Fiscella, R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Saf. 25:233-250, 2002.